AstraZeneca PLC Third quarter and nine months results 2012

Thursday, 25 October 2012

As expected, the revenue decline in the third quarter reflected the ongoing effect from the loss of exclusivity on several brands. Continued disciplined management of operating expenses and proceeds from the sale of Nexium OTC rights mitigated the impact of the revenue decline on Core operating profit. Financial targets for full year unchanged.

Third quarter and nine months results

Announced on Thursday 25 October 2012

Downloads

Webcast

View the webcast

AstraZeneca Contacts

Media Enquiries UK

Esra Erkal-Paler +44 20 7604 8030
Vanessa Rhodes +44 20 7604 8037

Investor Enquiries

James Ward-Lilley +44 20 7604 8122 mob: +44 7785 432613
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950
Ed Seage +1 302 886 4065 mob: +1 302 373 1361